Literature DB >> 24604627

Psychological therapies for thalassaemia.

Kofi A Anie1, Pia Massaglia.   

Abstract

BACKGROUND: Thalassaemia is a group of genetic blood disorders characterised by the absence or reduction in the production of haemoglobin. Severity is variable from less severe anaemia, through thalassaemia intermedia, to profound severe anaemia (thalassaemia major). In thalassaemia major other complications include growth retardation, bone deformation, and enlarged spleen. Blood transfusion is required to treat severe forms of thalassaemia, but this results in excessive accumulation of iron in the body (iron overload), removed mostly by a drug called desferrioxamine through 'chelation therapy'. Non-routine treatments are bone marrow transplantation (which is age restricted), and possibly hydroxyurea, designed to raise foetal haemoglobin level, thus reducing anaemia. In addition, psychological therapies seem appropriate to improving outcome and adherence to medical treatment.
OBJECTIVES: To examine the evidence that in people with thalassaemia, psychological treatments improve the ability to cope with the condition, and improve both medical and psychosocial outcomes. SEARCH
METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Searches on the Internet were also performed.Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 11 November 2013. SELECTION CRITERIA: All randomised or quasi-randomised controlled trials comparing the use of psychological intervention to no (psychological) intervention in people with thalassaemia. DATA COLLECTION AND ANALYSIS: No trials of psychological therapies have been found in the literature for inclusion in this review. MAIN
RESULTS: There are currently no results to be reported. AUTHORS'
CONCLUSIONS: As a chronic disease with a considerable role for self-management, psychological support seems appropriate for managing thalassaemia. However, from the information currently available, no conclusions can be made about the use of specific psychological therapies in thalassaemia. This systematic review has clearly identified the need for well-designed, adequately-powered, multicentre, randomised controlled trials assessing the effectiveness of specific psychological interventions for thalassaemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604627      PMCID: PMC7138048          DOI: 10.1002/14651858.CD002890.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 2.  The thalassaemias.

Authors:  D J Weatherall
Journal:  BMJ       Date:  1997-06-07

3.  Successful use of hydroxyurea in beta-thalassemia major.

Authors:  V R Arruda; C S Lima; S T Saad; F F Costa
Journal:  N Engl J Med       Date:  1997-03-27       Impact factor: 91.245

4.  Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy.

Authors:  M J Treadwell; L Weissman
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

5.  Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis.

Authors:  S Ratip; D Skuse; J Porter; B Wonke; A Yardumian; B Modell
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

6.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

Authors:  G M Brittenham; P M Griffith; A W Nienhuis; C E McLaren; N S Young; E E Tucker; C J Allen; D E Farrell; J W Harris
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

7.  Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

Authors:  B Modell; M Khan; M Darlison
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

8.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

9.  Marrow transplantation in patients with thalassemia responsive to iron chelation therapy.

Authors:  G Lucarelli; M Galimberti; P Polchi; E Angelucci; D Baronciani; C Giardini; M Andreani; F Agostinelli; F Albertini; R A Clift
Journal:  N Engl J Med       Date:  1993-09-16       Impact factor: 91.245

10.  Cluster randomised trials in the medical literature: two bibliometric surveys.

Authors:  J Martin Bland
Journal:  BMC Med Res Methodol       Date:  2004-08-13       Impact factor: 4.615

View more
  4 in total

1.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

2.  Cardiac MR images of thalassemia major patients with myocardial iron overload: a data note.

Authors:  Emad Shiae Ali; Mohamad Amin Bakhshali; Seyed Jafar Shoja Razavi; Hoorak Poorzand; Parvaneh Layegh
Journal:  BMC Res Notes       Date:  2021-08-19

3.  Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.

Authors:  Sefika Pinar Senol; Eyup Naci Tiftik; Selma Unal; Aydan Akdeniz; Bahar Tasdelen; Bahar Tunctan
Journal:  J Basic Clin Pharm       Date:  2016-03

4.  Quality of life and challenges experienced by the surviving adults with transfusion dependent thalassaemia in Malaysia: a cross sectional study.

Authors:  Wai Cheng Foong; Kooi Yau Chean; Fairuz Fadzilah Rahim; Ai Sim Goh; Seoh Leng Yeoh; Angeline Aing Chiee Yeoh
Journal:  Health Qual Life Outcomes       Date:  2022-01-08       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.